Authors: J R Curtis A O Westfall H Cheng K G Saag E Delzell
Publish Date: 2008/10/23
Volume: 20, Issue: 6, Pages: 973-978
Abstract
The comparative effectiveness of alendronate and risedronate has received limited evaluation Among 19063 new users of bisphosphonates risedronate users had a higher relative rate of hip fracture compared to alendronate users but the difference in absolute fracture rate was small We conclude that the agents have comparable efficacyBisphosphonates differ in their in vitro potency avidity for bone and rapidity of onset in clinical trials To address potential differences between bisphosphonates in comparative effectiveness we compared new users of alendronate and risedronate to determine if there were differences in the risk of clinical fractures at 1 year and beyondThere were no significant differences in fracture rates between alendronate users n = 12956 and risedronate users n = 6107 at 1 year Using all available data the rate of hip fracture was higher among risedronate users compared to alendronate users absolute rate difference approximately five per 1000 personyears Risedronate users had a higher relative rate RR of hip fracture RR = 177 95 CI 115–274 and similar rates of clinical vertebral and nonvertebral fractures compared to alendronate usersJC research grants Novartis Amgen Merck Proctor Gamble Eli Lilly consulting Roche speakers bureau Merck Procter and Gamble Eli Lilly Roche AW research grants Novartis HC research grants Amgen KGS research grants Novartis Amgen Aventis Merck Procter Gamble Eli Lilly Roche consulting or speaking Merck Proctor and Gamble Eli Lilly Roche Novartis Amgen ED research grants Amgen
Keywords: